Skip to main content

Table 3 Hazard ratios of death within five years according to LY6D expression in Cohorts I and II

From: Lymphocyte antigen 6 superfamily member D is a marker of urothelial and squamous differentiation: implications for risk stratification of bladder cancer

  Cohort I Cohort II
  Univariable Multivariable   Univariable Multivariable
  n (events) HR(95% CI) HR(95% CI) n (events) HR(95% CI) HR(95% CI)
Age
 Continuous 100 (45) 1.06 (1.03–1.09) 1.06 (1.02–1.09) 260 (82) 1.05 (1.02–1.08) 1.04 (1.01–1.08)
Gender
 Male 74 (33) 1.00 180 (59) 1.00
 Female 26 (12) 1.15 (0.60–2.24) 80 (23) 0.88 (0.54–1.42)
Stage
 pTa 45 (7) 1.00 1.00 114 (16) 1.00 1.00
 pT1 21 (14) 5.42 (2.18–13.47) 2.10 (0.69–6.37) 81 (24) 2.58 (1.37–4.87) 1.65 (0.80–3.57)
  ≥ pT2 34 (24) 7.98 (3.42–18.60) 3.39 (1.06–10.91) 65 (42) 8.14 (4.55–14.55) 3.47 (1.45–8.30)
Grade
 Low 47 (8) 1.00 1.00 126 (18) 1.00 1.00
 High 53 (37) 6.35 (2.95–13.71) 2.26 (0.76–6.68) 134 (64) 4.47 (2.64–7.54) 1.44 (0.65–3.20)
Histology
 Classic     209 (48) 1.00 1.00
 Squamous     14 (10) 6.12 (3.08–12.15) 2.39 (1.11–5.14)
 Other variant     37 (24) 4.44 (2.71–7.27) 2.04 (1.16–3.59)
LY6D expression
 Negative (0) 37 (24) 1.00 1.00 93 (38) 1.00 1.00
 Positive (1–2) 63 (21) 0.50 (0.25–0.81) 0.86 (0.47–1.60) 167 (44) 0.58 (0.37–0.89) 0.78 (0.48–1.25)
  1. Only cases in which LY6D could be assessed were included in all analyses
  2. Apart from LY6D expression, only factors with significant hazard ratios in the univariable analyses were
  3. included in the multivariable analyses.0 = Negative LY6D expression, 1 = ≤ 50% positive LY6D expression, 2 = > 50% LY6D expression